Standard BioTools completed the sale of its SomaLogic business to Illumina on January 30, 2026, receiving $350 million in upfront cash with up to $75 million in revenue-based earnouts through 2026. The transaction leaves the company with approximately $550 million in cash while retaining its mass cytometry and microfluidics businesses.

Cash Position vs. Market Valuation

With 384.6 million shares outstanding (per November 2025 10-Q), the company holds $1.43 per share in cash. The stock currently trades at $1.40, representing a price-to-cash ratio of 0.98—essentially at net cash with no value assigned to continuing operations.

The retained businesses generated $61.5 million in revenue over the first nine months of 2025, down 7% year-over-year. Q3 2025 revenue was $19.6 million, down 11% year-over-year, with management citing research funding constraints and macroeconomic pressures. The company is targeting positive adjusted EBITDA in 2026 for continuing operations.

Insider Positioning and Strategic Intent

Casdin Partners accumulated 11.6 million shares between August and December 2025 at an average price of approximately $1.30, investing over $15 million prior to the transaction close. This represents informed positioning ahead of the cash realization event.

Management explicitly stated the cash proceeds will "fuel our inorganic growth strategy," signaling M&A intent. The company now has a $550 million acquisition war chest in a business with a $538 million market capitalization—more deployable capital than the entire enterprise value.

Transaction Structure

Beyond the upfront payment, the deal includes a 2% royalty on SOMAmer NGS kit sales for ten years, providing optionality on Illumina's commercialization success. The earnout structure ties up to $75 million to SomaLogic's 2025-2026 revenue performance.

The valuation setup presents asymmetric risk-reward: downside is protected by the cash floor at current prices, while upside depends on management's ability to execute accretive acquisitions or improve margins in continuing operations. The market appears to be pricing in either significant cash burn or value-destructive M&A, creating a margin of safety for investors betting on mediocre execution rather than worst-case outcomes.